Cellectis (CLLS)
(Delayed Data from NSDQ)
$2.35 USD
-0.03 (-1.26%)
Updated Aug 28, 2024 12:26 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CLLS 2.35 -0.03(-1.26%)
Will CLLS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CLLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLLS
Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?
Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS)
CLLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cellectis (CLLS) Upgraded to Buy: Here's Why
After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS)
Iovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil
Other News for CLLS
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
Cellectis Reveals Promising Cancer Therapy Breakthrough
Cibus to Participate in Upcoming August Investor Events
Cellectis SA: Strong Buy Rating on Robust Pipeline and Financial Stability
Cibus: Q2 Earnings Snapshot